Reproductive health of women with fat metabolism disorders
https://doi.org/10.33667/2078-5631-2020-4-27-32
Abstract
Objective: to assess the reproductive health features of women with fat metabolism disorders and the safety of using combined oral contraception in them.
Materials and methods. 150 women of childbearing age (mean age 29.8 ± 4.7 years) were examined, which were divided into three groups depending on the type of impaired fat metabolism: the first group included patients with obesity and dyslipidemia (n = 50); the second group – women with obesity without dyslipidemia (n = 46); the third group – patients with a normal body mass index and dyslipidemia (n = 54). All patients underwent clinical and laboratory examination with the assessment of biochemical, metabolic and hormonal blood parameters. At the second stage of the study, the safety assessment of the use of combined oral contraceptive with chlormadinone acetate (COC–CMA) in women in need of pregnancy protection was performed.
Results. Women with fat metabolism disorders have a high prevalence of menstrual irregularities. The most commonly detected were polycystic ovary syndrome (PCOS), phenotypes A, C, D. In the absence of PCOS in obese women or patients with dyslipidemia at normal weight, the formation of endocrine pathology was observed, associated with hyperandrogenemia or a tendency to hypogonadotropic hypogonadism. Patients with obesity and dyslipidemia had the worst fertility profile and high prevalence of infertility and miscarriage. Taking COC–CMA did not have a significant effect on fat metabolism.
Conclusion. Dyslipidemia and obesity are independent factors in reproductive health problems. Clinical portraits of gynecological endocrine pathology in patients with obesity, dyslipidemia and their combination are different. The assessment of carbohydrate and fat metabolism should be considered one of the important components of the examination of patients with menstrual dysfunction or impaired fertility. COC–CMA can be considered the drug of choice for contraception in women with impaired fat metabolism.
About the Authors
E. R. Vedzizheva
City Clinical Hospital n. a. D. D. Pletnyov
Russian Federation
Moscow
Russian Federation
Moscow
I. V. Kuznetsova
Higher Medical School
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Аганезова Н. В., Аганезов С. С. Ожирение и репродуктивное здоровье женщины. Акушерство и гинекология. 2016; 6: 18–25.
2. Иловайская И. А. Влияние ожирения у женщин на фертильность и вынашивание беременности. РМЖ. 2016; 1: 32–37.
3. Санта-Мария Фернандес Д. О., Кузнецова И. В., Гитель Е. П. Комплексная терапия нарушений менструального цикла у пациенток раннего репродуктивного возраста с избыточной массой тела и ожирением. Эффективная фармакотерапия. 2015; 5: 26–32.
4. Galliano D., Bellver J. Female obesity: short- and long-term consequences on the offspring. Gynecol Endocrinol. 2013; 29 (7): 626–31.
5. Crujeiras AB, Casanueva FF. Obesity and the reproductive system disorders: epigenetics as a potential bridge. Hum Reprod Update. 2015; 21 (2): 249–61.
6. Balsan GA, Vieira JL, Oliveira AM, Portal VL. Relationship between adiponectin, obesity and insulin resistance. Rev Assoc Med Bras (1992). 2015; 61 (1): 72–80.
7. Seif MW, Diamond K, Nickkho-Amiry M. Obesity and menstrual disorders. Best Pract Res Clin Obstet Gynaecol. 2015; 29 (4): 516–27.
8. Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013; 56 (3): 137–142.
9. Kowalska K, Ściskalska M, Bizoń A, Śliwińska-Mossoń M, Milnerowicz H. Influence of oral contraceptives on lipid profile and paraoxonase and commonly hepatic enzymes activities. J Clin Lab Anal. 2018; 32 (1): e22194.
10. Сухих Г. Т., Прилепская В. Н., Вартапетова Н. В., и др. Национальные медицинские критерии приемлемости методов контрацепции РФ (клинические рекомендации). ООО «Верди». М., 2012. 242 с.
11. Panidis D, Tziomalos K, Papadakis E et al.Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. Hormones (Athens). 2015; 14 (3): 431–7.
12. Можинская Ю. В., Белик С. Н., Подгорный И. В., Аветисян З. Е. Ожирение как фактор риска репродуктивных неудач. Синергия Наук. 2017; 16: 732–740.
13. Behboudi-Gandevani S, Ramezani Tehrani F et al. Insulinresistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies. Gynecol Endocrinol. 2016; 32 (5): 343–353.
14. Чернуха Г. Е., Блинова И. В., Купрашвили М. И. Эндокринно-метаболические характеристики больных с различными фенотипами синдрома поликистозных яичников. Акушерство и гинекология. 2011; 2: 70–76.
15. Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013; 11 (1): 41–47.
16. Kerscher M, Reuther T, Krueger N, Buntrock H. Effects of an oral contraceptive containing chlormadinone acetate and ethinylestradiol on hair and skin quality in women wishing to use hormonal contraception. J Eur Acad Dermatol Venereol. 2013; 27 (5): 601–608.
17. Mayeda ER, Torgal AH, Westhoff CL.Weight and Body Composition Changes During Oral Contraceptive Use in Obese and Normal Weight Women. J Womens Health (Larchmt) 2014; 23 (1): 38–43.
18. Winkler UH, Röhm P, Höschen K. An openlabel, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol / 2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables. Contraception. 2010; 81: 391–400.
Review
For citations:
Vedzizheva E.R., Kuznetsova I.V. Reproductive health of women with fat metabolism disorders. Medical alphabet. 2020;(4):27-32. (In Russ.) https://doi.org/10.33667/2078-5631-2020-4-27-32
Views:
688
Email this article 